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The link between oestrogen and the growth and development of
some breast cancers has long been recognized (Beatson, 1896;
Boyd, 1900), and there is substantial evidence that circulating
oestrogens promote the proliferation of breast cancer (Jordan,
1976; Knazek et al, 1977). Many current therapies for breast
cancer involve hormonal manipulation, with oestrogen-depriva-
tion of the tumour being an established method of treatment. Drug
therapy can achieve this goal either by antagonizing the effects of
circulating oestrogens on receptors at the tumour site using anti-
oestrogens, or by reducing the level of oestrogen within the body
using drugs such as aromatase inhibitors (Howell and Dowsett,
1997). 
Tamoxifen is currently the endocrine drug of choice for 
the treatment of early breast cancer in patients with oestrogen
receptor-positive disease. The effects of tamoxifen in breast 
cancer appear to be primarily related to its anti-oestrogenic
activity/oestrogen-receptor (ER) antagonist activity, although other
mechanisms of action may also be important (Jaiyesimi et al, 1995). 
Aromatase inhibitors are a class of compounds that act systemi-
cally to inhibit oestrogen synthesis in tissues, by inhibiting the
enzyme aromatase, which catalyses the conversion of androgens
(androstenedione and testosterone) to oestrogens (oestrone and
oestradiol). In postmenopausal women, oestrogens are mostly
derived from adrenal androgens being converted by aromatase in
peripheral tissues (Grodin et al, 1973; Brodie and Njar, 1998).
Aromatase is also present in many breast carcinomas where it may
provide an important source of oestrogenic stimulation (Miller and
O’Neill, 1987). 
Anastrozole (Arimidex) is a third-generation non-steroidal
aromatase inhibitor, which is both potent and selective for the
enzyme. It is given orally, is well tolerated, and provides almost
complete oestrogen suppression both systemically and intratu-
mourally (Geisler et al, 1996, 1999). Anastrozole is effective 
in treating advanced breast cancer (Buzdar et al, 1996) and at a
dose of 1 mg once-daily, it significantly increases survival time
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http://www.bjcancer.comcompared with megestrol acetate (median follow-up 31 months)
(Buzdar et al, 1998). Recently, it was shown to be at least as effec-
tive as tamoxifen (20 mg o.d.) for first-line treatment of post-
menopausal advanced breast cancer (Bonneterre et al, 2000;
Nabholtz et al, 2000). One of these studies was conducted in North
America and the other in Europe, Australia, New Zealand, South
Africa and South America. In patients with tumours known to be
ER-positive and/or progesterone receptor (PgR)-positive, anastro-
zole significantly prolonged time to disease progression compared
with tamoxifen (median values of 10.7 and 6.4 months for anastro-
zole and tamoxifen, respectively, P = 0.022) (Nabholtz et al, 2000). 
From the different and potentially complementary modes of
action of tamoxifen and anastrozole, it is possible that using both
agents in combination may provide a more effective method of
treating breast cancer in postmenopausal women. A study referred
to as the ‘Arimidex and Tamoxifen Alone, or in Combination
(ATAC)’ trial is currently underway to investigate this hypothesis.
The trial, which has recruited over 9300 patients, is designed to
compare the efficacy and safety of anastrozole and the combination
of anastrozole plus tamoxifen with that of tamoxifen alone, as adju-
vant treatment for postmenopausal women with early breast cancer,
who have completed their primary therapy (surgery with or without
radiotherapy and/or chemotherapy) (Houghton and Baum, 1998). 
Before initiating this large clinical trial programme it was 
noted that the prototype aromatase inhibitor, aminoglutethimide,
reduced blood levels of tamoxifen by more than 50% when given
in combination (Lien et al, 1990). Hence a pilot study was
conducted to determine whether or not anastrozole had any effect
on tamoxifen blood levels, and thus, potentially any impact on the
clinical efficacy of tamoxifen (Dowsett et al, 1999a). That study
showed that anastrozole did not affect the pharmacokinetics of
tamoxifen when the 2 drugs were given in combination to post-
menopausal women with early breast cancer. Additionally, anas-
trozole remained an effective suppressant of oestradiol when given
in combination with tamoxifen (Dowsett et al, 1999a). However,
no assessment was made of the major active metabolite of tamox-
ifen, desmethyltamoxifen, which has a similar pharmacological
profile to tamoxifen but with concentrations approximately 50%
higher than the parent drug. In addition, the effect of tamoxifen on
the pharmacokinetics of anastrozole could not be directly assessed
with the design of that study. However, preclinical data in rats
suggest that there is no synergism between anastrozole and tamox-
ifen (Brodie et al, 1999, the half-life of anastrozole in the rat is
very different compared with a patient (8 hours in the rat and 50
hours in a patient); Dukes, 1997). Therefore, it cannot be assumed
that the lack of synergistic activity of these agents in a rat can be
extrapolated to the clinical situation. 
We now report data from an assessment of the pharmacokinetics
of both anastrozole and tamoxifen when given alone or in combina-
tion as adjuvant endocrine therapy for early breast cancer as deter-
mined in a sub-protocol of the ATAC trial. Following the initial
pharmacokinetic assessments, further data were taken from a sepa-
rate ATAC protocol in order to evaluate oestradiol suppression. 
PATIENTS AND METHODS 
Study design 
This was a sub-protocol of the ATAC trial, which is a randomized,
double-blind, multicentre study. The sub-protocol was designed
to compare the pharmacokinetics of the combination of 
anastrozole plus tamoxifen with those of anastrozole alone or
tamoxifen alone when used as adjuvant treatment for early breast
cancer in postmenopausal women (Houghton and Baum, 1998). 
The study was designed and monitored to comply with the
ethical principles of Good Clinical Practice (GCP) in accordance
with the Declaration of Helsinki. All patients included in the study
had given their informed consent. 
The primary assessments were the steady-state trough plasma
concentrations of tamoxifen, desmethyltamoxifen, and anastro-
zole, measured at 24 ±4 hours after the previous dose of treatment. 
There was no intent to measure baseline or on-treatment oestra-
diol levels in the PK sub-protocol, but measuring the effects of
anastrozole with or without tamoxifen on oestradiol levels
became desirable after the pharmacokinetic data became avail-
able. Thus, this information was sought from a separate ATAC
sub-protocol, which looked at bone mineral density in a total of
167 patients. This cohort was chosen since this sub-protocol
required blood samples to be taken from patients at baseline and 3
months following treatment, allowing the impact of drugs on the
proportional suppression of oestradiol to be established and
compared between the treatments. 
Patient population 
All patients were initially recruited into the ATAC trial and were
required to be postmenopausal, have a diagnosis of early breast
cancer, have completed all primary treatment and chemotherapy
(if given), and be suitable to receive adjuvant endocrine therapy. 
The inclusion criteria for the patients recruited to both the bone
mineral density and pharmacokinetic studies were the same. To be
eligible for this pharmacokinetics subprotocol, all patients had to
have been participating in the ATAC trial for at least 3 months,
have taken their medication in the morning and have been fully
compliant over the preceding 14 days before the study assessments
were performed. Each trial investigator or pharmacist was respon-
sible for the maintenance of drug accountability records, which
consisted of documentation of receipt, dispensing, and the return
of trial medication. Drug dispensing was documented by attaching
the tear-off portion of the drug label to each patient record (or case
report form in North America) and this was initialled and dated by
the investigator. At the end of the trial, patients were asked to
return all unused drugs and a note of the number of returned 
tablets was entered on to the patient record or case report 
form. The completed forms were then signed off and dated by the
investigator. 
Exclusion criteria for the pharmacokinetic sub-protocol were
concurrent treatment with diazepam, oral administration of keto-
conazole or related antifungal compounds, or drugs that might
affect steroid hormone status and/or tamoxifen steady-state levels
(cytotoxic chemotherapy or other hormonal treatments for breast
cancer). Exclusion criteria for the bone mineral density protocol
above that of the main sub-protocol were patients who have:
received hormone replacement therapy or bisphosphate therapy
within the previous 12 months prior to recruitment; had a bone
fracture in the previous 6 months prior to recruitment; chronic
renal/liver impairments; malabsorption syndrome; endocrine
disorders including hyperthyroidism, untreated thyroid disease,
Cushing’s syndrome or pituitary disease; or patients taking corti-
costeroids or anti-convulsants. Demographic data from this and
other sub-protocols, as well as from the ATAC trial as a whole,
will be published in the future. 
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Patients enrolled in the ATAC trial were randomized on a 1:1:1
basis into 1 of 3 treatment schedules (active anastrozole 1 mg o.d.
and tamoxifen placebo o.d., active tamoxifen 20 mg o.d. and
anastrozole placebo o.d., or active anastrozole 1 mg o.d. and
active tamoxifen 20 mg o.d.). Patients at 24 centres from 6 coun-
tries that agreed to participate in the sub-protocol were screened
for additional eligibility criteria for entry 3 months after their
randomization into the ATAC trial. In order that the blinding of
the ATAC trial would not be compromised, patients were issued
with a unique identifying number specific to this sub-protocol,
which could not be linked to the patient identifier in the ATAC
trial. 
Assessments 
In the pharmacokinetic sub-protocol, patients were required to
give only one 15 ml blood sample, after steady-state levels had
been achieved (3 months after treatment randomization). The
elimination half-lives of tamoxifen, desmethyltamoxifen, and
anastrozole are 4–7 days (Adam, 1981a, 1981b); 6.7–12 days
(Adam, 1981a, 1981b; Mould et al, 1986a, 1986b; De-vos et al,
1989), and 40–50 hours (Yates et al, 1996), respectively.
Therefore, by taking the samples 3 months after treatment random-
ization ensured that steady-state would be reached by this time. In
this sample, trough (Cmin) plasma concentrations of anastrozole,
tamoxifen, and desmethyltamoxifen were measured. For the
purposes of this study, trough levels were defined as the plasma
concentration of drug 24 hours after the previous dose. However,
for practical reasons blood samples withdrawn between 20 and 28
hours (24 ± 4 hours) after the last dose were acceptable. Because
trough levels were required, it was important that no medication
was taken on the day of assessment until after the blood sample
was withdrawn. If a patient had taken medication within the
previous 24 ± 4 hours, she was asked to give her blood sample at
another visit. 
Plasma levels of tamoxifen and desmethyltamoxifen were
analysed according to the high-performance liquid chromatog-
raphy (HPLC) method described by Johnston et al (1993). Overall,
recovery varied from 79% to 93% and was corrected for by the
internal recovery control. The intra-assay coefficient of variation
was 2.2% at a mean level of 135 ng ml–1. The sensitivity limit for
the detection of tamoxifen was 0.5 ng ml–1 and for desmethyl-
tamoxifen was 0.275 ng ml–1. Plasma levels of anastrozole were
determined using a validated method involving solvent extraction,
capillary gas chromatography, and separation with electron
capture detection (ECD) (Bock et al, 1997). The sensitivity limit
for the detection of anastrozole was 3.0 ng ml–1. 
Oestradiol levels were assessed from a blood sample taken at
baseline and at 3 months following treatment; the analytical
method for this had a sensitivity limit of 3 pmol l–1 and has been
previously described (Dowsett et al, 1987). 
Statistical analysis 
The primary assessments of the sub-protocol were the steady-state
plasma concentrations of anastrozole (Bock et al, 1997), tamoxifen
and desmethyltamoxifen. For the steady-state Cmin plasma levels of
tamoxifen and desmethyltamoxifen, comparisons were made
between samples from patients treated with either tamoxifen alone
or with anastrozole plus tamoxifen. For the steady-state Cmin
plasma levels of anastrozole, comparisons were made between
samples from patients treated with either anastrozole alone or
anastrozole in combination with tamoxifen. 
To demonstrate equivalence between 2 treatment groups in
terms of plasma levels, the 90% confidence interval for the ratio of
the geometric means (combination/monotherapy) was required to
lie within the interval > 0.8 to 1.25. A population of 110 patients
per treatment arm was required to demonstrate equivalence of the
plasma levels of tamoxifen, desmethyltamoxifen, and anastrozole
with a minimum 90% power. 
All comparisons were analysed using analysis of variance. All
plasma levels were log (base e) transformed prior to analysis. 
The results were back transformed and presented in terms of the
geometric means. The treatment effect was the ratio of 
the geometric mean of the combination group divided by the
geometric mean of the associated monotherapy group. The appro-
priate equivalence test criteria was the 90% confidence interval for
the ratio of geometric mean values. Equivalence was concluded if
the 90% confidence interval lay entirely within the (0.8, 1.25)
interval. 
For oestradiol levels, the comparison between the anastrozole
and combination treatment groups was assessed using analysis of
variance. The percentage reduction in oestradiol levels was deter-
mined with the baseline fitted as a covariate. Oestradiol levels
were log (base e) transformed prior to analysis. The results were
back transformed and presented in terms of the adjusted (for base-
line oestradiol) geometric least square means (GLS Means), repre-
senting the oestradiol level at 3 months as a proportion of the level
at baseline. The 90% confidence interval of the ratio of GLS
Means was calculated along with estimated percentage reductions
in oestradiol in each treatment group. 
RESULTS 
Patient characteristics 
A total of 357 patients (138 anastrozole 1 mg o.d., 113 tamoxifen 
1 mg o.d., and 106 anastrozole co-administered with tamoxifen)
were recruited into this sub-protocol from 24 international centres.
The groups were well balanced with respect to demographic char-
acteristics (Table 1). 10 patients were excluded from the pharma-
cokinetic analyses because the results of laboratory tests did not
correspond with those that would be anticipated from their
recorded treatment allocation, highlighting uncertainties in the
actual treatment received. In 2 patients recorded as receiving anas-
trozole alone, tamoxifen was identified at a concentration in the
range of those seen clinically; one patient recorded as receiving
anastrozole alone had undetectable anastrozole levels; 5 patients
recorded as receiving anastrozole alone also had trace levels of
tamoxifen; and in 2 patients recorded as receiving tamoxifen alone
there were detectable low levels of anastrozole. The demographic
characteristics of the patients enrolled in the bone sub-protocol,
whose blood samples were analysed for plasma oestradiol levels,
were comparable to those of the patients in the pharmacokinetic
sub-protocol of the ATAC trial. Because the study looking at bone
mineral density is ongoing, we were unable to break the drug code
and carry out statistical tests. However, the demographics of the
bone density sub-protocol were comparable with the patients from
the main ATAC trial. 
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desmethyltamoxifen 
There was very little difference between the mean steady-state trough
plasma concentrations of tamoxifen and desmethyltamoxifen in
patients receiving tamoxifen when compared with those of patients
receiving anastrozole in combination with tamoxifen (Table 2). The
mean level of tamoxifen in both groups was approximately 100
ng ml–1 and levels of desmethyltamoxifen were almost 3-fold those
of tamoxifen. Fewer values of desmethyltamoxifen were available
since a batch of analyses failed quality control criteria and insuffi-
cient sample was available for repeat analysis. The ratio of the
geometric mean values ((anastrozole and tamoxifen group)/tamox-
ifen group) was 1.01 for tamoxifen (90% confidence interval from
0.91 to 1.11), and 1.05 for desmethyltamoxifen (90% confidence
interval from 0.94 to 1.16). This indicates that the tamoxifen and
desmethyltamoxifen blood levels measured in patients receiving
tamoxifen alone were equivalent to those in patients receiving
tamoxifen in combination with anastrozole. 
Plasma concentrations of anastrozole 
The mean steady-state trough plasma concentration of anastrozole
in patients receiving anastrozole monotherapy was 37.4 ± 15.2
ng ml–1. In patients co-administered with tamoxifen and anastro-
zole, the mean steady-state trough plasma concentration of anas-
trozole was found to be 27.7 ± 11.3 ng ml–1 (Table 2). 
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Table 1 Patient characteristics 
Demographic Anastrozole  Tamoxifen  Anastrozole  Bone  sub
characteristics (1 mg o.d.) (20 mg o.d.) + tamoxifen protocol
Number of patients 138 113 106 302 
Age (years) 
n 138 111 105 301 
Median 65 63 62 65 
Minimum 42 43 40 42 
Maximum 87 88 84 86 
BMI 
n 130 107 105 288 
Median 26.7 26.3 26.9 28 
Minimum 22.7 23.5 20.3 17.6 
Maximum 54.9 36.2 32.1 52.3 
Origin (number of patients) 
Caucasian 132 (95.7%) 104 (92.0%) 102 (96.2%) 272 (90.1%) 
Black/Afro-Caribbean 2 ( 1.4%) 1 (0.9%) 1 (0.9%) 4 (1.3%) 
Hispanic 1 ( 0.7%) 1 (0.9%) 0 2 (0.6%) 
Asian 1 ( 0.7%) 0 0 0 
Mixed 2 ( 1.4%) 4 (3.5%) 1 (0.9%) 17 (6.2%) 
Other 0 0 1 (0.9%) 2 (0.6%) 
Not recorded 0 3 (2.7%) 1 (0.9%) 5 (1.8%) 
Table 2 Steady-state trough plasma concentrations (Cmin) of tamoxifen, desmethyltamoxifen and anastrozole 
Tamoxifen  Anastrozole (1 mg o.d.) Anastrozole  
(20 mg o.d.) and tamoxifen (20 mg o.d.) (1 mg o.d.)
(n = 111) (n = 105) (n = 131) 
Tamoxifen
n 104 99 – 
Arithmetic mean ± SD (ng/ml) 103.8 ± 40.9 103.8 ± 45.6 – 
Geometric mean 94.8 95.3 – 
Ratio of geometric mean 
(anastrozole+tamoxifen)/tamoxifen 1.01 
90% Cl (lower-upper) (0.91–1.11) 
Desmethyltamoxifen 
n 76 76 – 
Arithmetic mean ± SD (ng/ml) 286.6 ± 107.8 293.8 ± 98.9 – 
Geometric mean 265.1 277.6 – 
Ratio of geometric mean 
(anastrozole+tamoxifen)/tamoxifen 1.05 
90% Cl (lower-upper) (0.94–1.16) 
Anastrozole 
n – 104 130 
Arithmetic mean ± SD (ng/ml) – 27.7 ± 11.3 37.4 ± 15.2 
Geometric mean – 25.5 34.7 
Ratio of geometric mean 
(anastrozole+tamoxifen)/anastrozole 0.73 
90% Cl (lower-upper) (0.67–0.80) The ratio of the geometric mean values ((anastrozole and
tamoxifen group)/anastrozole group) for anastrozole was 0.73
(90% confidence interval from 0.67 to 0.80). This indicates that
the mean anastrozole levels were a mean 27% lower (P < 0.001) in
the presence of tamoxifen than with anastrozole alone, and there-
fore equivalence could not be concluded. 
Plasma concentrations of oestradiol 
Of the 167 patients whose plasma oestradiol concentrations were
measured before and after 3 months’ treatment, 55 patients were on
anastrozole, 62 were on tamoxifen and 50 were on anastrozole plus
tamoxifen. Geometric mean levels were 21.3, 19.3 and 21.6 pmol l–1,
respectively before treatment and 3.7, 20.9 and 3.6 pmol l–1, respec-
tively after 3 months’ treatment (Figure 1). The GLS Means for the
ratio of 3-month values to baseline values were 0.174 for anastro-
zole alone and 0.169 for anastrozole plus tamoxifen, indicating
that percentage suppression was 82.6 and 83.1%, respectively. The
ratio of the GLS Means ((anastrozole + tamoxifen)/anastrozole)
was 0.97 and the 90% confidence interval was 0.86 to 1.10. The
percentage of oestradiol concentrations below the assay detection
limit was 43.6 for anastrozole alone and 38.5 for the combination.
Thus, the effect of anastrozole on oestradiol suppression was very
similar whether administered alone or in combination with tam-
oxifen; none of the small differences in the data approached 
statistical significance. 
The pretreatment oestradiol levels showed a highly significant
(P = 0.0001) positive correlation with weight and body mass index
but no relationship with height or smoking status. There was a
positive correlation with age, and this approached statistical 
significance (P = 0.06). 
DISCUSSION 
The aim of the ongoing ATAC study is to compare the efficacy
and safety of anastrozole alone with those of tamoxifen alone or
the combination of anastrozole with tamoxifen, as adjuvant
treatment for postmenopausal women with early breast cancer,
who have completed their primary therapy (surgery with or
without radiotherapy and/or chemotherapy). As part of the
larger ATAC programme, a number of sub-protocols have been
undertaken, of which the pharmacokinetic sub-protocol is
reported here. 
Given the different modes of action of anastrozole and tamox-
ifen (Howell and Dowsett, 1997), there is a rationale for
combining these 2 drugs due to the potential for synergy and
increased efficacy. It was, therefore, necessary to determine
whether or not the pharmacokinetics of the 2 drugs were affected
when given in combination. It was considered particularly impor-
tant to determine whether or not there was any effect on tamoxifen
levels since tamoxifen is widely accepted to be the endocrine drug
of choice for the treatment of early breast cancer in patients with
oestrogen receptor-positive disease (Early Breast Cancer Trialists’
Collaborative Group, 1992, 1998). The relevance of looking for
possible interactions between anastrozole and tamoxifen was
emphasized by the finding that the non-specific aromatase
inhibitor, aminoglutethimide, had an interaction with tamoxifen
resulting in a greater than 50% reduction in plasma tamoxifen
levels (Lien et al, 1990). It was suggested that this reduction might
have affected the clinical efficacy of tamoxifen when the 2 drugs
were combined. This interaction was attributed to an action of
aminoglutethimide whereby it induces the metabolism of tamox-
ifen. In contrast to the effects of aminoglutethimide on tamoxifen,
however, anastrozole was previously found not to interact with the
metabolism of tamoxifen in a study designed specifically to
address that possibility (Dowsett et al, 1999a). 
The findings of the present study were consistent with the
results of this earlier pilot study (Dowsett et al, 1999a), showing
that steady-state trough plasma tamoxifen concentrations were
similar in patients treated with tamoxifen monotherapy or in
combination with anastrozole. Mean tamoxifen levels were similar
to those reported in that earlier study. Additionally, in the present
study, the plasma levels of the biologically active metabolite,
desmethyltamoxifen, were unaffected by the presence of anastro-
zole, indicating that no substantial effect on the major metabolic
pathway of tamoxifen was induced by anastrozole. 
This sub-protocol also set out to determine whether or not
tamoxifen had any effect upon anastrozole blood levels, and, since
the effectiveness of anastrozole as a treatment for breast cancer
(Buzdar et al, 1998; Nabholtz et al, 2000) is related to its effective-
ness as an oestrogen suppressant (Geisler et al, 1996), to compare
the oestradiol suppression achieved by anastrozole alone with its
effect in combination with tamoxifen. Co-administration of anas-
trozole with tamoxifen resulted in a mean 27% decrease in steady-
state trough plasma anastrozole levels compared with those
observed in patients administered anastrozole alone. 
The finding of lower blood anastrozole levels when combined
with tamoxifen administration is not unique to anastrozole; similar
findings have been reported previously for the non-steroidal
aromatase inhibitor, letrozole. In a study of 12 postmenopausal
women with advanced breast cancer, the pharmacokinetics of
combined treatment with tamoxifen (20 mg day–1) and letrozole
(2.5 mg day–1) were examined. Plasma levels of letrozole were
reduced by a mean 37.6% (90%Cl: 31.6–43.2%) during combina-
tion therapy (P < 0.0001) (Dowsett et al, 1999b). The mechanism
was postulated to be a consequence of an induction of letrozole-
metabolizing enzymes by tamoxifen, which would result in more
rapid metabolism of letrozole and hence a reduction in plasma
levels. However, this potential mechanism was not addressed in
the study, nor has it been assessed in subsequent studies. It is
possible that a similar mechanism may be responsible for the
reduced plasma levels of anastrozole observed in this sub-
protocol, although again this has not been investigated, and
remains to be elucidated. 
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Figure 1 Plasma concentrations of oestradiol measured before and after 
3 months’ treatment with anastrozole (1 mg o.d.), tamoxifen (20 mg o.d.), or
anastrozole and tamoxifen in combination (1 mg o.d. and 20 mg o.d.
respectively). Limit of detection for oestradiol, 3 pmol l–1
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)There are data available that suggest that the observed mean
27% reduction in anastrozole levels would not have significantly
affected the degree of oestradiol suppression, and hence the clin-
ical efficacy of anastrozole. In the pilot combination study
(Dowsett et al, 1999a), suppression of serum oestradiol in patients
who received anastrozole in combination with tamoxifen was to
the limit of detection of the assay used (3 pmol l–1). In an earlier
study, administration of both 0.5 and 1 mg anastrozole once-daily
achieved a greater than 80% reduction in the mean oestradiol
levels (Yates et al, 1996). The present sub-protocol was designed
to assess subjects who had already received treatment for 3 months
prior to entry, such that pretreatment blood samples were not avail-
able to assess the relative suppression of oestrogen levels in the
same patients in whom pharmacokinetic data were available. 
Thus the opportunity was also taken to compare oestrogen
levels in a further set of samples obtained from a separate sub-
protocol of ATAC (to assess the effect of the treatment on bone
metabolism) in which pretreatment and on-treatment samples at
steady state were available. The demographic measures were
comparable for both groups of patients. The inclusion criteria for
the bone sub-protocol were the same as for this pharmacokinetic
study, and although there were some exclusion criteria above those
of the main ATAC sub-protocol, it is likely that the oestradiol-
suppressing effects we report for the patients assessed for bone
metabolism are the same as would be seen in the patients assessed
for the pharmacokinetics of anastrozole and tamoxifen. The data
revealed a very similar degree of suppression of oestradiol levels
with anastrozole alone and in combination with tamoxifen,
confirming expectations of no perceptible reduction in the phar-
macological effectiveness of the lower anastrozole levels. 
Tamoxifen alone had no significant effect on oestradiol levels.
This is consistent with previous studies (Dowsett et al, 1999a), but
was important to confirm in the present study since a pharmaco-
logical effect of tamoxifen on plasma oestradiol could have
confounded the study of whether the lower plasma levels of anas-
trozole affected its effects on oestrogen suppression. The positive
correlation of the pretreatment values of oestradiol with weight,
BMI and (marginally) with age are also consistent with expecta-
tions since there are well-described positive relationships between
peripheral aromatase activity and each of these parameters
(Grodin et al, 1973; MacDonald et al, 1978). Demonstration of
these relationships in this dataset suggests that the population
studied may be considered representative of the postmenopausal
population. 
Overall the data from this study are reassuring in that the lack of
effect of anastrozole on tamoxifen levels indicates that no reduc-
tion in the efficacy of tamoxifen would be anticipated in the
combination arm of the ATAC trial. Thus the benefits of tamoxifen
in this arm should not be lower than those in the tamoxifen
monotherapy arm. The over-riding question, therefore, is whether
or not combining anastrozole with tamoxifen will achieve
increased efficacy when compared with tamoxifen alone.
Definitive conclusions as to whether or not the efficacy of anastro-
zole is affected by the addition of tamoxifen cannot be made until
the results of the main ATAC trial have been analysed. However, it
does appear that the observed interaction between tamoxifen and
anastrozole is unlikely to reduce the levels of anastrozole suffi-
ciently to reduce its oestrogen-suppressive effects. 
In conclusion, the results confirm that, in postmenopausal
women with early breast cancer, co-administration of anastrozole
does not affect steady-state trough plasma concentrations of
tamoxifen. Steady-state trough plasma concentrations of the
metabolite of tamoxifen, desmethyltamoxifen, are also unaffected.
The observed reduction in the steady-state trough plasma concen-
trations of anastrozole in the presence of tamoxifen has no signifi-
cant effect on the oestradiol suppressive effects of anastrozole.
These results, therefore, indicate that the observed interaction is
unlikely to be of clinical significance whenever anastrozole or
tamoxifen are administered together. The results of the main
ATAC trial will shed further light on these findings. 
ACKNOWLEDGEMENTS 
Members of the Writing Group for this paper are asterisked. 
Principal Investigator for the ATAC Pharmacokinetic Sub-
protocol *Prof M Dowsett, The Royal Marsden Hospital, London,
UK. 
APPENDIX 1– ATAC TRIAL STEERING
COMMITTEE MEMBERSHIP 
Prof M Baum (Chairman and Principal Investigator for the main
ATAC Trial), University College London, London, UK; Prof M
Dowsett, The Royal Marsden Hospital, London, UK; Dr M
Coibion, Institut Bordet, Bruxelles, Belgium; Prof AR Bianco,
Universita Degli Studi Di Napoli Federico II, Napoli Italy; *Dr J
Cuzick, Imperial Cancer Research Fund Labs, London, UK; Prof
W D George, Western Infirmary, Glasgow, UK; Sr J Gray, Belfast
City Hospital, Belfast, UK; *Dr A Howell, Christie Hospital and
Holt Radium Institute, Manchester, UK; Mrs J Houghton, Dr N
Williams, CRC and UCL Cancer Trials Centre, UCL Medical
School, London, UK, UK; Prof J Sloane, Royal Liverpool
University Hospital, Liverpool, UK; Dr J Tobias, The Meyerstein
Institute of Clinical Oncology, Middlesex Hospital, London, UK;
Dr A Buzdar, The University of Texas, M. D. Anderson 
Cancer Centre, Houston, USA; *Dr I Jackson, Dr T Sahmoud, 
Mr J Gallagher, Mr A Webster, AstraZeneca Pharmaceuticals,
Macclesfield, UK. 
APPENDIX II – PRINCIPAL INVESTIGATORS IN
THE ATAC PHARMACOKINETIC SUB-PROTOCOL 
Prof. D Gangji, Erasme Hospital, Brussels, Belgium; Dr K
Petrakova, Masarykuv onkologicky ústav, Brno, Czech Republic;
Dr B Konopasek, Onkologicka klinika UK, Praha, Czech
Republic; Dr P Mares, Onkologicka klinika UK, Praha, Czech
Republic; Dr P Vodvarka, Radioterapeuticka klinika, Ostrava-
Poruba, Czech Republic; Dr Ana Alcazar, Hospital Reynaldo dos
Santos, Vila Franca de Xira, Portugal; Dr Ondina Campos,
Maternidade Bissaya Barreto, Coimbra, Portugal; Dr A Maxwell,
Durban, South Africa; Prof Goedhals, Nationale Hospital,
Bloemfontein, South Africa; Dr D Hacking, Durban Oncoclogy
Centre, Durban, South Africa; Dr G Landers, Parklands Hospital,
Durban, South Africa; Dr L Smith, Nationale Hospital,
Bloemfontein, South Africa; Dr DA Vorobiof, Sandton Oncology,
Sandton, South Africa; Prof ID Werner, New Groote Schuur
Hospital, Cape Town, South Africa; Professor R Blamey, City
Hospital, Nottingham, UK; Prof R Coleman, Western Park Hospital,
Sheffield, UK; Dr Robert J Grieve, Walsgrave Hospital, Coventry,
UK; Dr T Hickish, Royal Bournemouth Hospital, Bournemouth,
Dorset, UK; Prof A Howell, Christie Hospital and Withington
Hospital, Manchester, UK; Mr JC Nicholls, St. Albans City
322 The ATAC Trialists’ Group 
British Journal of Cancer (2001) 85(3), 317–324 © 2001 Cancer Research CampaignHospital, St. Albans, Herts, UK; Mr S Nicholson, York District
Hospital, York, UK; Mr S Raymond, St. Albans City Hospital, St
Albans, Herts, UK; Mr A Salman, Worthing Hospital, Worthing,
Sussex, UK; Dr J. Blum, Texas Oncology, PA, Dallas, TX, USA;
Dr R. Clark, Hematology/Oncology Associates, Jackson, MI,
USA; Dr A. Lyss, Missouri Baptist Cancer Center, St. Louis, MO,
USA; Dr G. Miletello, Baton Rouge General Regional Cancer
Center, Baton Roughe, LA, USA; Dr J. Sternberg, Clinical
Investigation Specialists, Inc, Little Rock, AR, USA. 
APPENDIX III – ADDITIONAL TRIAL
COMMITTEES AND
COLLABORATIVE/OPERATIONAL GROUPS 
International Coordinating Committee 
Prof J Forbes, Newcastle Mater Misericordiae Hospital, NSW,
Australia; Dr M Coibion, Institut Bordet, Brussels, Belgium; 
Dr JM Nabholtz, Cross Cancer Institute, Edmonton, Alberta,
Canada; Dr J P Guastalla, Centre Leon Berard, Lyon, France;
Professor Dr W Distler, Universitatsklinikum Dresden, Dresden,
Germany; *Professor Dr J G M Klijn, Dr. Daniel den Hoed Kliniek
and University Hospital Rotterdam, Rotterdam, The Netherlands;
Dr T Nagykalnai, Uzsoki U Hospital, Budapest, Hungary; Dr A
Nicolucci, Givio Co-ordinating Centre, Consorzio Mario Negri
Sud, Centro Di Ricerchi Farmacologichi, E Biomedichi, Chieta,
Italy; Prof A R Bianco, Universita Federico II, Napoli, Italy; Dr M
Constenla, Hospital Motelcelo, Pontevedra, Spain; Dr U Nylen,
Radiumhemmet, Karolinska sjukhuset, Stockholm, Sweden; Prof
A Howell, Christie Hospital, Manchester, UK; Mr R Sainsbury,
Huddersfield Royal Infirmary, Huddersfield, UK; Prof R E
Mansel, University of Wales College of Medicine, Cardiff, UK;
Professor D George, Beatson Oncology Center, Western Infirmary,
Glasgow, UK; Dr A U Buzdar, MD Anderson Center, University
of Texas, Houston, TX, USA; Dr G Y Locker, Evanston Hospital,
Kellogg Cancer Care Center, Evanston IL, USA. 
International Project Team 
J Gallagher, I Jackson, T Sahmoud, AstraZeneca Pharmaceuticals,
Macclesfield, UK; J Houghton, N Williams, CRC and UCL
Cancer Trials Centre, UCL Medical School, London, UK; A
Nicolucci, Mario Negri Institute, Chieta, Italy; S Pollard, Northern
Yorkshire Clinical Trials Research Unit, Leeds, UK; P Stroner,
SCTN Central Office, Information and Statistics Division,
Edinburgh, UK. 
Independent Data Monitoring Committee 
Dr M Buyse, International Institute for Drug Development (ID
squared), Brussels, Belgium; Dr R Margolese, Mc Gill University,
The Sir Mortimer B Davis Jewish General Hospital, Montreal,
Quebec, Canada; Mr J M A Northover, ICRF Colorectal Cancer
Unit, St Mark’s Hospital, Harrow, Middlesex, UK. 
REFERENCES 
Adam H (1981a) Pharmacokinetic studies with Nolvadex. Rev Endocrine Related
Cancer Suppl 9: 131–143 
Adam HK (1981b) What we know and don’t know about the pharmacokinetics of
tamoxifen. Special Rep Chemotherap Effects of Nolvadex 29–34 651.794 IC PL
Symposium. Clinical applications of oncology San Diego 22 May 1981 
Beatson GT (1896) On the treatment of inoperable cases of carcinoma in mamma;
suggestion for new method of treatment with illustrative cases. Lancet 2:
104–107 
Bock MJH, Bara I, LeDonne N, Martz A and Dyroff M (1997) Validated assay for
the quantification of anastrozole in human plasma by capillary gas
chromatography/63Ni electron capture detection. J Chrom B 700: 131–138 
Bonneterre J, Thurlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski
P, Vergote I, Webster A, Steinberg M and von Euler M, for the Arimidex Study
Group (2000) Anastrozole versus tamoxifen as first-line therapy for advanced
breast cancer in 668 postmenopausal women: results of the TARGET
(Tamoxifen or Arimidex™ Randomized Group Efficacy and Tolerability)
study. J Clin Oncol 18: 3748–3757 
Boyd S (1900) On oophorectomy in cancer of the breast. Br Med J ii: 1161–1167 
Brodie A, Lu Q, Liu Y and Long B (1999) Aromatase inhibitors and their antitumor
effects in model systems. Endocr Relat Cancer 6 (2): 205–210 
Brodie AMH and Njar VCO (1998) Aromatase inhibitors in advanced breast cancer:
mechanism of action and clinical implications. J Steroid Biochem Mol Biol 66:
1–10 
Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W,
Wolter JM, Azab M, Webster A and Plourde PV for the Arimidex Study Group
(1996) Anastrozole, a potent and selective aromatase inhibitor, versus
megestrol acetate in postmenopausal women with advanced breast cancer:
result of overview analysis of two phase III trials. J Clin Oncol 14: 2000–2011 
Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W,
Wolter JM, Steinberg M, Webster A and Lee D for the Arimidex Study Group
(1998) Anastrozole versus megestrol acetate in the treatment of
postmenopausal women with advanced breast carcinoma: Results of a survival
update based on a combined analysis of data from two mature phase III trials.
Cancer 83(8): 1142–1152 
De-vos D, Mould G and Stevenson D (1989) The bioavailability of tamoxifen: new
findings and their clinical implications. Curr Ther Res 46: 703–708 
Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffconte SL and
Coombes RC (1987) Use of the aromatase inhibitor 4-hydroxyandrostenedione
in postmenopausal breast cancer: optimization of therapeutic dose and route.
Cancer Res 47: 1957–1961 
Dowsett M, Tobias JS, Howell A, Blackman GM, Welch H, King N, Ponzone R, von
Euler M and Baum M (1999a) The effect of anastrozole on the
pharmacokinetics of tamoxifen in postmenopausal women with early breast
cancer. Br J Cancer 79(2): 311–315 
Dowsett M, Pfister C, Johnston SR, Mules DW, Houston SJ, Verbeek JA, Gundacker
H, Sioufi A and Smith IE (1999b) Impact of tamoxifen on the
pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in
postmenopausal women with breast cancer. Clin Cancer Res 9(9): 2338–2343 
Dukes M (1997) The relevance of preclinical models to the treatment of
postmenopausal breast cancer. Oncology 54 (Suppl 2): 6–10 
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of
early breast cancer by hormonal, cytotoxic, or immune therapy. 133
randomised trials involving 31,000 recurrences and 24,000 deaths among
75,000 women. Lancet 339: 1–15, 71–85 
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early
breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467 
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO and
Lønning PE (1996) Influence of anastrozole (Arimidex), a selective, non-
steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen
levels in postmenopausal women with breast cancer. Br J Cancer 74:
1286–1291 
Geisler J, Bernsten H, Ottestad L, Lindtjorn B, Dowsett M, Lønning PE (1999)
Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression
of intra-tumor estrogen levels. Proc Am Soc Clin Oncol 18: 82a Abs 311 
Grodin JM, Siiteri PK and MacDonald PC (1973) Source of estrogen production in
postmenopausal women. J Clin Endocrinol Metab 36: 207–214 
Houghton J and Baum M, ATAC Study Group (1998) ‘Arimidex’, tamoxifen alone
or in combination (ATAC) adjuvant trial in post-menopausal breast cancer. Eur
J Cancer 34 (Suppl 5): S83 Abs 385. Abstracts from the 1st European Breast
Cancer Conference, Florence, 29 Sep-3 Oct 1998 
Howell A and Dowsett M (1997) Recent advances in endocrine therapy of breast
cancer. Br Med J 315 (7112): 863–866 
Jaiyesimi IA, Buzdar AU, Decker DA and Hortobagyi G (1995) Use of tamoxifen
for breast cancer: twenty-eight years later. J Clin Oncol 13(2): 513–529 
Johnston SRD, Haynes BP, Sacks NPM, McKinna JA, Griggs LJ, Jarman M, Baum
M, Smith IE and Dowsett M (1993) Effect of oestrogen receptor status and time
PK of arimidex and tamoxifen alone or in combination 323
British Journal of Cancer (2001) 85(3), 317–324 © 2001 Cancer Research Campaignon the intratumoural accumulation of tamoxifen and N-desmethyltamoxifen
following short-term therapy in human breast cancer. Breast Cancer Res Treat
28: 241–250 
Jordan VC (1976) Effect of tamoxifen (ICI 46474) on initiation and growth of
DMBA-induced rat mammary carcinoma. Eur J Cancer 12: 419–424 
Knazek RA, Lippmann ME and Chopra HC (1977) Formation of solid human
mammary carcinoma in vitro. J Natl Cancer Inst 58: 419–422 
Lien EA, Anker G, Lönning PE, Solheim E and Veland PM (1990) Decreased serum
concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
Cancer Res 50: 5851–5857 
MacDonald PC, Edman CD, Hempsell DL, Porter JC and Siiteri PK (1978) Effect of
obesity on conversion of plasma androstenedione to oestrone in
postmenopausal women with and without endometrial cancer. Am J Obstet
Gynecol 130: 448–455 
Miller WR and O’Neill J (1987) The importance of local synthesis of estrogen
within the breast. Steroids 50(4–6): 537–548 
Mould GP, Stevenson D, Briggs RJ and De-vos D (1986a) A re-evaluation of the
pharmacokinetics of tamoxifen. Acta Pharmacol Toxicol 59 (Suppl 5): 310 Abs 
Mould G, Stevenson D, Briggs RJ, Guelen PJM, Slee PHTJ and De-vos D (1986b)
New insights into the tamoxifen pharmacokinetics constitute a basis for a
loading dose scheme. Eur J Cancer and Clin Oncol 22: 732 Abs 
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M,
Webster A and von Euler M (2000) Anastrozole is superior to tamoxifen as
first-line therapy for advanced breast cancer in postmenopausal women: results
of a North American multicenter randomized trial. J Clin Oncol 18: 3758–3776 
Yates RA, Dowsett M, Fisher GV, Selen A and Wyld PJ (1996) Arimidex (ZD1033):
a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
Br J Cancer 73(4): 543–548 
324 The ATAC Trialists’ Group 
British Journal of Cancer (2001) 85(3), 317–324 © 2001 Cancer Research Campaign